Quantcast
Last updated on April 23, 2014 at 12:08 EDT

Latest Omecamtiv Mecarbil Stories

2013-09-26 12:29:24

--No safety concerns and reduction in cardiovascular events observed through three years of follow up in the MYDICAR high dose group-- SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced the full three year long-term follow up results from Phase 2a of the CUPID 1 trial in the online publication of Circulation...

2013-09-23 16:24:11

Session will highlight the results of recent heart failure trials ORLANDO, Fla., Sept. 23, 2013 /PRNewswire/ -- The Heart Failure Society of America (HFSA) 17(th) Annual Scientific Meeting will include a Late Breaking Clinical Trials Symposium today. The session will describe the results of recent trials and discuss their implications for the care of patients with heart failure. The Late Breaking Clinical Trials session will feature a variety of presentations on the results of recent trials...

2013-09-03 04:21:08

First Trial to Evaluate Cardiac Myosin Activator in Patients with Acute Heart Failure Presented at ESC Congress 2013 THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Sept. 3, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Cytokinetics Incorporated (NASDAQ: CYTK) today announced the first presentation of data from the ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study at the ESC Congress 2013, organized by the European...